Les archives de recherche sur les mitochondries

Une bibliothèque de publications scientifiques sélectionnées avec soin et évaluées par des pairs, explorant les dernières avancées en matière d'énergie cellulaire, d'
de résilience métabolique et de la science de la vitalité humaine.

Mitochondrial Complex I Deficiency and Alzheimer’s-Like Brain Changes

Study Title: Mitochondrial complex I deficiency induces Alzheimer’s disease-like signatures that are reversible by targeted therapy

Citation:
Gao et al., 2025 · Alzheimer’s & Dementia

What the Study Found: This study examined whether mitochondrial complex I deficiency can produce Alzheimer’s disease-like molecular changes in the brain. Researchers used Ndufs4 knockout mice, a model of impaired mitochondrial complex I function, and analyzed cortico-hippocampal brain tissue. They found disrupted mitochondrial homeostasis, altered energy metabolism, and changes in synaptic gene expression. These molecular patterns resembled signatures seen in human late-onset Alzheimer’s disease and familial Alzheimer’s disease mouse models. Importantly, these Alzheimer’s-like changes appeared independently of amyloid beta or phosphorylated tau. Treatment with the mitochondria-targeted compound CP2 partially reversed several of these molecular changes, with some sex-specific differences in response.

What this means in real life: This study suggests that impaired mitochondrial energy biology may help drive Alzheimer’s-like changes in the brain, rather than simply appearing after damage has already occurred. In this model, reduced complex I activity was enough to shift brain tissue toward patterns associated with Alzheimer’s disease. This does not mean mitochondrial support treats Alzheimer’s disease, and this was not a human clinical trial. It does support the idea that mitochondrial function is closely tied to brain aging, synaptic health, and the biology of memory and cognitive resilience.

Clinical Relevance: Mouse study, Alzheimer’s disease biology, mitochondrial complex I deficiency, brain aging, and transcriptomic analysis model; not direct clinical trial evidence.

Related Content: